PF-04905428   Click here for help

GtoPdb Ligand ID: 9062

Synonyms: CE-224,535 | CE-224535 | compound 3 [PMID: 21782426] | compound 33 [PMID: 21565499]
Immunopharmacology Ligand
Compound class: Synthetic organic
Comment: PF-04905428 is an investigational purinergic receptor 2 (P2X7) antagonist [2,4], with potential antiinflammatory action in various conditions such as arthritis, allergies, asthma, COPD, autoimmune diseases and other disorders.. PF-04905428 is one of the compounds claimed in patent US6974812 [1].
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 8
Hydrogen bond donors 3
Rotatable bonds 9
Topological polar surface area 135.16
Molecular weight 480.18
XLogP 2.51
No. Lipinski's rules broken 0
Click here for help
Canonical SMILES COCC(Cn1c(=O)cnn(c1=O)c1ccc(c(c1)C(=O)NCC1(O)CCCCCC1)Cl)O
Isomeric SMILES COC[C@@H](Cn1c(=O)cnn(c1=O)c1ccc(c(c1)C(=O)NCC1(O)CCCCCC1)Cl)O
InChI InChI=1S/C22H29ClN4O6/c1-33-13-16(28)12-26-19(29)11-25-27(21(26)31)15-6-7-18(23)17(10-15)20(30)24-14-22(32)8-4-2-3-5-9-22/h6-7,10-11,16,28,32H,2-5,8-9,12-14H2,1H3,(H,24,30)/t16-/m1/s1
No information available.
Summary of Clinical Use Click here for help
A Phase 3 clinical trial in patients with rheumatoid arthritis (RA: NCT00628095) has been completed. Results showed PF-04905428 (CE-224,535) was not effective in treating RA [3].
Mechanism Of Action and Pharmacodynamic Effects Click here for help
P2X7 receptor activation promotes inflammasome-mediated proteolytic processing of proIL-1β and release of the mature cytokine- a pro-inflammatory action. P2X7 receptor antagonists should block IL-1 posttranslational processing and reduce release of IL-1β- an anti-inflammatory action.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT00628095 Study of CE-224,535 A Twice Daily Pill To Control Rheumatoid Arthritis In Patients Who Have Not Totally Improved With Methotrexate Phase 2/Phase 3 Interventional Pfizer